Patents by Inventor Sang-Ryeol Shim

Sang-Ryeol Shim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230265196
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed cell Death 1 receptor (PD-1) and a vascular endothelial growth factor receptor-2 (VEGFR-2) antagonist, and the use of the combination therapies for the treatment of a cancer. In an embodiment, the cancer is a glioblastoma, a breast cancer, a triple negative breast cancer, a metastatic breast cancer, or a metastatic triple negative breast cancer.
    Type: Application
    Filed: September 2, 2021
    Publication date: August 24, 2023
    Inventors: Seon Young Lee, Weon Sup Lee, Jin-San Yoo, Sang Ryeol Shim
  • Patent number: 10597457
    Abstract: The present disclosure relates to an antibody specifically binding to epidermal growth factor receptor variant III (EGFRvIII), to nucleic acid coding the antibody, to a vector comprising the nucleic acid, to a host cell, to a preparation method of the antibody, and to a pharmaceutical composition comprising the antibody as an active ingredient for treating a cancer or a tumor.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: March 24, 2020
    Assignee: PHARMABCINE INC.
    Inventors: Jae Bong Yoon, Jinsang Yoo, Jin-San Yoo, Weon Sup Lee, Sung-Woo Kim, Sang Ryeol Shim, Sang Soon Byun, Youngae Lee, Hyuk Joon Lee, Do-yun Kim, Jinhee Choi
  • Patent number: 10155817
    Abstract: The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: December 18, 2018
    Assignee: PharmAbcine Inc.
    Inventors: Joong Kyu Kim, Jin San Yoo, Sang Hoon Lee, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim, Jin Sang Yoo, Young Ae Lee, Mi Ju Park, Sang Soon Byun, Hyuk Joon Lee, Do Yun Kim, Yeun Ju Kim, Jin Hee Choi, Kyung Hee Nahm, Ju Ryung Nam, Jong Geun Jeong, Bo Young Jeong, Eun Jin Lee, Seon Young Lee, In Sook Park, Jin Sook Lee, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh
  • Patent number: 10125194
    Abstract: The present invention relates to: a dual targeting antibody of a novel form having a water-soluble ligand fused to the N-terminus of a heavy chain or light chain of an antibody; a DNA encoding the dual targeting antibody; a recombinant expression vector containing the DNA; a host cell which is transformed with the recombinant expression vector; a method for preparing the dual targeting antibody by culturing the host cell; and a pharmaceutical composition including the dual targeting antibody.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: November 13, 2018
    Assignee: PHARMABCINE INC.
    Inventors: Jin San Yoo, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim
  • Patent number: 10106622
    Abstract: Provided are an antibody specifically bound to c-Met (c-Met-specific antibody) or fragments thereof, and more specifically, a fully human antibody having high affinity and specificity to c-Met isolated from human Fv(ScFv) phage library, a polynucleotide encoding the antibody, a recombinant vector containing the polynucleotide, a cell transformed with the recombinant vector, and a method of producing the c-Met-specific antibody by culturing the cell, wherein the c-Met-specific antibody may effectively control activity of c-Met in vivo.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: October 23, 2018
    Assignee: PHARMABCINE INC.
    Inventors: Jinsang Yoo, Ju Ryoung Nam, Jin San Yoo, Sung-Woo Kim, Weon Sup Lee, Sang Ryeol Shim, Sang Soon Byun, Miju Park, Hyuk Joon Lee, Do Yun Kim, Yeon Ju Kim, Mi Ae Jeon, Jinhee Choi, Youngae Lee, Kyoung Hee Nahm, Boyoung Jeong, Seon Young Lee, Jong Geun Jeong, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh, Eun Hee Lee, Ji Hye Jeong
  • Publication number: 20180208660
    Abstract: The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.
    Type: Application
    Filed: March 14, 2018
    Publication date: July 26, 2018
    Applicant: PharmAbcine Inc.
    Inventors: Joong Kyu Kim, Jin San Yoo, Sang Hoon Lee, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim, Jin Sang Yoo, Young Ae Lee, Mi Ju Park, Sang Soon Byun, Hyuk Joon Lee, Do Yun Kim, Yeun Ju Kim, Jin Hee Choi, Kyung Hee Nahm, Ju Ryung Nam, Jong Geun Jeong, Bo Young Jeong, Eun Jin Lee, Seon Young Lee, In Sook Park, Jin Sook Lee, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh
  • Patent number: 9963512
    Abstract: The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: May 8, 2018
    Assignee: PharmAbcine Inc.
    Inventors: Joong Kyu Kim, Jin San Yoo, Sang Hoon Lee, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim, Jin Sang Yoo, Young Ae Lee, Mi Ju Park, Sang Soon Byun, Hyuk Joon Lee, Do Yun Kim, Yeun Ju Kim, Jin Hee Choi, Kyung Hee Nahm, Ju Ryung Nam, Jong Geun Jeong, Bo Young Jeong, Eun Jin Lee, Seon Young Lee, In Sook Park, Jin Sook Lee, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh
  • Publication number: 20170327585
    Abstract: The present disclosure relates to an antibody specifically binding to epidermal growth factor receptor variant III (EGFRvIII), to nucleic acid coding the antibody, to a vector comprising the nucleic acid, to a host cell, to a preparation method of the antibody, and to a pharmaceutical composition comprising the antibody as an active ingredient for treating a cancer or a tumor.
    Type: Application
    Filed: November 25, 2014
    Publication date: November 16, 2017
    Inventors: Jae Bong Yoon, Jinsang Yoo, Jin-San Yoo, Weon Sup Lee, Sung-Woo Kim, Sang Ryeol Shim, Sang Soon Byun, Youngae Lee, Hyuk Joon Lee, Do-yun Kim, Jinhee Choi
  • Publication number: 20170233492
    Abstract: Provided are an antibody specifically bound to c-Met (c-Met-specific antibody) or fragments thereof, and more specifically, a fully human antibody having high affinity and specificity to c-Met isolated from human Fv(ScFv) phage library, a polynucleotide encoding the antibody, a recombinant vector containing the polynucleotide, a cell transformed with the recombinant vector, and a method of producing the c-Met-specific antibody by culturing the cell, wherein the c-Met-specific antibody may effectively control activity of c-Met in vivo.
    Type: Application
    Filed: July 28, 2015
    Publication date: August 17, 2017
    Inventors: Jinsang Yoo, Ju Ryoung Nam, Jin San Yoo, Sung-Woo Kim, Weon Sup Lee, Sang Ryeol Shim, Sang Soon Byun, Miju Park, Hyuk Joon Lee, Do Yun Kim, Yeon Ju Kim, Mi Ae Jeon, Jinhee Choi, Youngae Lee, Kyoung Hee Nahm, Boyoung Jeong, Seon Young Lee, Jong Geun Jeong, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh, Eun Hee Lee, Ji Hye Jeong
  • Patent number: 9249219
    Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: February 2, 2016
    Assignee: PHARMABCINE INC.
    Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
  • Patent number: 9249220
    Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: February 2, 2016
    Assignee: PHARMABCINE INC.
    Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
  • Publication number: 20150315277
    Abstract: The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.
    Type: Application
    Filed: November 20, 2013
    Publication date: November 5, 2015
    Applicant: PharmAbcine Inc.
    Inventors: Joong Kyu Kim, Jin San Yoo, Sang Hoon Lee, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim, Jin Sang Yoo, Young Ae Lee, Mi Ju Park, Sang Soon Byun, Hyuk Joon Lee, Do Yun Kim, Yeun Ju Kim, Jin Hee Choi, Kyung Hee Nahm, Ju Ryung Nam, Jong Geun Jeong, Bo Young Jeong, Eun Jin Lee, Seon Young Lee, In Sook Park, Jin Sook Lee, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh
  • Patent number: 9150650
    Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: October 6, 2015
    Assignee: PHARMABCINE INC.
    Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Se-mi Kim, Sang-Seok Koh
  • Publication number: 20140288274
    Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 25, 2014
    Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
  • Publication number: 20140275488
    Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Applicant: PHARMABCINE INC.
    Inventors: Jin-San YOO, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
  • Publication number: 20120065380
    Abstract: The present invention relates to: a dual targeting antibody of a novel form having a water-soluble ligand fused to the N-terminus of a heavy chain or light chain of an antibody; a DNA encoding the dual targeting antibody; a recombinant expression vector containing the DNA; a host cell which is transformed with the recombinant expression vector; a method for preparing the dual targeting antibody by culturing the host cell; and a pharmaceutical composition including the dual targeting antibody.
    Type: Application
    Filed: July 22, 2009
    Publication date: March 15, 2012
    Applicant: Pharmabcine Inc.
    Inventors: Jin San Yoo, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim
  • Publication number: 20110065176
    Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.
    Type: Application
    Filed: June 26, 2007
    Publication date: March 17, 2011
    Applicant: Korea Research Institute of BioScience and BioTechnology
    Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong- Eun Kang, Do-Yun Kim, Joon Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae -Won Jeon, Dong- Sup Lee, Young-Woo Park, Geun - Bae Rha, Hyun-Sook Jang, Hyeon- Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh